Cardiol Therapeutics Inc. (TSX:CRDL) (OTC:CRTPF) has released a video regarding the progress it has made in development of its pharmaceutical-grade CBD compound. According to President and CEO David Elsley, there are a number of reasons to be excited about the future of Cardiol and the emerging CBD market. “Cannabidiol is in high demand and short supply in many regions of the world. We have a state-of-the-art formulation and a state-of-the-art supply chain capable of meeting that demand with the purest most advanced form of that cannabidiol. We see a significant revenue opportunity because our supply chain is positioned to manufacture one million grams of pure pharmaceutical cannabidiol at the highest level of purity in the industry today.”

Elsley sees the cannabidiol market as a $100 million opportunity based on current CBD price structures. “The average retail price for cannabidiol in a less-pure form than what we’re offering is $100 or more per gram, so it’s a $100 million opportunity and we can supply that opportunity this year,” said Elsley during the video. The company is currently researching the anti-inflammatory effects of cannabidiol on heart patients when the compound is directly delivered to the site of a specific injury.


Watch the full video here.

Click here to connect with Cardiol Therapeutics (TSX:CRDL) for an investor presentation. 

 Matica Enterprises Inc. (CSE: MMJ) (OTCQB: MMJFF) (FSE: 39N) (“Matica” or the “Company”) reports the Company has granted 6,500,000 stock options exercisable at $0.05 for five years from date of grant. These include 4,000,000 options to two officers (who are also directors) and, 2,500,000 to two consultants.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

Keep reading... Show less

The Company welcomes adult-use customers at its eight dispensaries across the state and will create 120 new jobs in surrounding communities

– Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced it will begin serving adult-use consumers across its eight dispensaries in Arizona .

Keep reading... Show less

Harvest Health & Recreation Inc. (“Harvest”) (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the launch of recreational cannabis sales in Arizona .

Keep reading... Show less

Jason Mitchell Co-Founder, Director and Chief Executive Officer, HempFusion Wellness Inc. (“HempFusion” or the “Company”) (TSX: CBD.U), and his team joined David Chelich Sector Head, Global Energy and Diversified Industries, TMX Group, to celebrate the Company’s new listing on Toronto Stock Exchange and open the market.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

The Horizons Psychedelic Stock Index ETF index is expected to start trading on Tuesday, January 26, under the ticker PSYK on the NEO exchange.

Keep reading... Show less